As a result, the beneficial impact of GLP-1R agonist on NAFLD observed in vivo, either in humans or animals, could be attributed partially to the ability of these agents to reduce hepatic inflammation. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.